BIOSANTE PHARMACEUTICALS INC Form 8-K August 14, 2003

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 14, 2003

BIOSANTE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware 0-28637 58-2301143

(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number)

111 Barclay Boulevard Lincolnshire, Illinois

60069 (Address of Principal Executive Offices) (Zip Code)

(847) 478-0500

(Registrant s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, If Changed Since Last Report)

Item 7. Financial	Statements and Exhibits.
(a)	Financial Statements of Businesses Acquired.
Not Applicable	
(b)	Pro Forma Financial Information.
Not Applicable	
(c)	Exhibits.
Exhibit No.	Description
Ex. 99.1	Press Release dated August 14, 2003 (filed herewith electronically).
Item 12. Results o	f Operations and Financial Condition.
On August 14, 2003 condition. Attached	B, BioSante issued a press release announcing BioSante s second quarter 2003 financial results of operations and financial hereto as Exhibit 99.1 is a copy of BioSante s press release dated August 14, 2003.
	SIGNATURE
Pursuant to the requundersigned hereun	direments of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the to duly authorized.
BIOSANTE PHAI	RMACEUTICALS, INC.
	By: /s/ Phillip B. Donenberg

Phillip B. Donenberg

Chief Financial Officer, Treasurer and Secretary

Dated: August 14, 2003

BIOSANTE PHARMACEUTICALS, INC.

FORM 8-K

Exhibit Index

Exhibit		
No.	Description	Method of Filing
99.1	Press Release of BioSante Pharmaceuticals, Inc. issued August 14, 2003	Filed herewith

3